Loading
Before a new cancer drug from a university is given to people, a separate laboratory should have repeated the main experiment showing it works.
Industry routinely replicates academic findings internally before investing, and reports that a majority fail. Academic and small-biotech investigational new drug applications rest on the originating lab's data. Requiring, or funding through translational programmes, an independent replication of the pivotal efficacy experiment (in the same model, blinded, pre-registered) before first-in-human dosing would catch non-reproducible programmes before patients are exposed.
Shares Funders set aside a fixed share of budget for independent replication, Preclinical results do not reproduce.
Shares Paid independent statistical review for preclinical papers that inform trials, Preclinical results do not reproduce.
Shares Multi-laboratory preclinical trials as the standard for go/no-go decisions, Preclinical results do not reproduce.
Shares Funders set aside a fixed share of budget for independent replication, Preclinical results do not reproduce.
Shares Funders set aside a fixed share of budget for independent replication, Preclinical results do not reproduce.
Shares Preclinical results do not reproduce, The valley of death between lab and product.
Shares Preclinical results do not reproduce, The valley of death between lab and product.
Shares Preclinical results do not reproduce, The valley of death between lab and product.